Patent Application
20070244158
The present invention relates to a piperidine compound having an excellent activity of tachykinin receptor antagonist, and a process for preparing the piperidine compound.
Tachykinin is a general name for a group of neuropeptides, and there have been known substance P (hereinafter referred to as “SP”), neurokinin-A, and neurokinin-B in mammals. These peptides are known to exhibit various kinds of biological activities by binding their corresponding receptors which exist in vivo (neurokinin-1, neurokinin-2, neurokinin-3). Among them, SP is one of those which have been studied the longest and in detail. Its existence was confirmed in an extract of horse intestinal tube in 1931, and it was a peptide comprising 11 amino acids, whose structure was determined in 1971.
SP exists widely in central and peripheral nervous systems, and it has physiological activities such as vasodilative action, vascular permeability promoting action, smooth muscle contracting action, neuronal excitatory action, salivary action, diuretic action, immunological action, etc., as well as a function of neurotransmitter of the primary sensory neuron. Especially, it is known that SP released from the terminal of posterior horn of spinal cord upon pain impulse transfers pain information to the secondary sensory neuron, and that SP released from the peripheral terminus induces an inflammatory response via its receptors. From these facts, SP is considered to be involved in various diseases (for example, pain, inflammation, allergy, pollakiuria, urinary incontinence, respiratory disease, mental disorder, depression, anxiety, emesis, etc.), and also, SP is considered to be involved in Alzheimer-type dementia [Review: Physiological Reviews, vol. 73, pp. 229-308 (1993), Journal of Autonomic Pharmacology, vol. 13, pp. 23-93 (1993)].
Currently, as a therapeutic agent for the above-mentioned various diseases (especially for emesis, depression, urinary disorder, etc.), there have not been discovered yet any compound having an excellent tachykinin receptor antagonistic action (specifically, SP receptor antagonistic action), and having sufficiently satisfying safety and sustainability (metabolism, dynamics in vivo, and absorption), etc. Therefore, a compound has been sought for which has an excellent tachykinin receptor antagonistic action, and has sufficiently satisfying clinical effect as the therapeutic agent.
Accordingly, an object of the present invention is to provide a compound having excellent tachykinin receptor antagonistic action, and having a clinical satisfying effect in terms of safety, sustainability (metabolism, dynamics in vivo and absorption), etc.
The present invention relates to a piperidine compound represented by the formula [I]:
In the present invention, Ring A represents an optionally substituted benzene ring, and a substituent of the benzene ring is exemplified by an optionally substituted alkyl group, a halogen atom, cyano group, hydroxyl group which may be protected or an alkoxy group. Ring A may have 1 to 3 of these substituent(s) which are the same or different.
In the present invention, Ring B represents an optionally substituted benzene ring, and a substituent of the benzene ring is exemplified by a haloalkyl group, a halogen atom, cyano group, phenyl group, a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s), an alkyl group, hydroxyl group which may be protected or an alkoxy group. Ring B may have 1 to 3 of these substituent(s) which are the same or different.
A preferred example of Ring A and Ring B in the compound of the present invention is exemplified by a compound wherein Ring A is a benzene ring of the formula:
and Ring B is a benzene ring of the formula:
wherein A1, A2 and A3 are the same or different, and each is hydrogen atom, a halogen atom, an optionally substituted alkyl group, hydroxyl group which may be protected or an alkoxy group, B1, B2 and B3 are the same or different, and each is hydrogen atom, a haloalkyl group, a halogen atom, cyano group, phenyl group, a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s), an alkyl group, hydroxyl group which may be protected or an alkoxy group. The substituent for the optionally substituted alkyl group is exemplified by a halogen atom, etc. The haloalkyl group is exemplified by an alkyl group substituted by 1 to 3 halogen atoms which may be the same or different from each other, and specifically mentioned a trihalogenoalkyl group. The trihalogenoalkyl group is exemplified by trifluoromethyl group or trichloromethyl group, etc. The heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s) is exemplified by tetrazolyl group.
In the present invention, the protective group for the optionally protected hydroxyl group is exemplified by a conventionally used protective group such as an optionally substituted arylalkyl group, an optionally substituted silyl group, an acyl group, etc. Of these, preferred is exemplified by an arylalkyl group such as benzyl group, phenethyl group, etc., a substituted silyl group such as tert-butyldimethylsilyl group, tert-butyldiphenylsilyl group, etc., an acyl group such as formyl group, acetyl group, propionyl group, malonyl group, acryloyl group, benzoyl group, etc.
In the present invention, R1 represents hydrogen atom or a substituent for amino group, and the substituent of the amino group in R1 is exemplified by an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted amino group, a substituted carbonyl group, a substituted sulfonyl group or an optionally substituted heterocyclic group.
Of these, R1 is preferably an optionally substituted alkyl group, an optionally substituted carbonyl group or an optionally substituted heterocyclic group, and R1 is further preferable a substituted carbonyl group or an optionally substituted heterocyclic group.
In the present invention, the substituent of the optionally substituted alkyl group of R1 is exemplified by an alkoxy group, a halogen atom, an alkoxycarbonyl group, morpholinocarbonyl group, a dialkylaminocarbonyl group, an optionally substituted heterocyclic group, hydroxyl group, a hydroxyalkylaminocarbonyloxy group or an alkylpiperazinocarbonyl group. The substituent of the optionally substituted heterocyclic group is exemplified by an alkanoyl group optionally substituted by hydroxyl group, or oxo group. The substituent(s) for the heterocyclic group may be the same or different from each other, and the number thereof may be 1 or 2. The heterocyclic group is exemplified by a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s). The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc.
In the present invention, the substituent of the optionally substituted cycloalkyl group of R1 is exemplified by an alkyl group, hydroxyl group, etc.
In the present invention, the substituent of the optionally substituted aryl group of R1 is exemplified by hydroxyl group, an alkyl group, cyano group, a halogen atom, etc. The aryl group is exemplified by phenyl group, naphthyl group, anthracenyl group or phenanthrenyl group.
In the present invention, the substituent of the optionally substituted amino group of R1 is exemplified by
The substituent of the optionally substituted alkyl group in the above-mentioned (1) is exemplified by hydroxyl group, a dialkylaminocarbonyl group, an alkoxy group, a dialkylamino group, cyano group, morpholino group, pyridyl group or a halogen atom.
The substituent of the substituted cycloalkyl group of the above-mentioned (2) is exemplified by hydroxyl group, an alkyl group, cyano group, a halogen atom, etc.
The substituent of the optionally substituted aryl group of substituent the above-mentioned (3) is exemplified by hydroxyl group, an alkyl group, cyano group, a halogen atom, etc. The aryl group is exemplified by phenyl group, naphthyl group, anthracenyl group or phenanthrenyl group.
The heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s) of the above-mentioned (4) is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc. Of these heterocyclic groups, suitably used are pyridyl group, pyrrolyl group, piperazinyl group, quinolyl group, piperidinyl group, pyrimidinyl group, thiazolyl group, pyrazinyl group, morpholino group, indolyl group, cinnolinyl group, furyl group, thienyl group, pyrrolidinyl group, imidazolidinyl group, etc. The substituent of the heterocyclic group is exemplified by a dialkylamino group, an alkoxycarbonyl group, an alkyl group, an alkoxy group, oxo group, hydroxyl group or a halogen atom.
In the present invention, the substituent of the substituted carbonyl group of R1 is exemplified by
The substituent of the optionally substituted alkyl group of the above-mentioned (1) is exemplified by
The substituent of the substituted carbonylamino group of the above-mentioned (II) is exemplified by (i) hydroxyl group, (ii) an optionally substituted alkyl group or (iii) an optionally substituted heterocyclic group, etc. The substituent of the optionally substituted alkyl group of the above-mentioned (ii) is exemplified by hydroxyl group or a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s), and the heterocyclic group may have a substituent(s). The substituent of the heterocyclic group is exemplified by oxo group, hydroxyl group, an alkanoyl group or an alkyl group. The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc. The substituent of the optionally substituted heterocyclic group of the above-mentioned (iii) is exemplified by an alkanoyl group optionally substituted by hydroxyl group, oxo group or hydroxyl group. The heterocyclic group is exemplified by a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s). The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc.
The substituent of the optionally substituted aminocarbonyl group of the above-mentioned (III) is exemplified by (i) an optionally substituted alkyl group or (ii) an optionally substituted heterocyclic group. The substituent of the optionally substituted alkyl group of the above-mentioned (i) is exemplified by hydroxyl group or a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s), and the heterocyclic group may have a substituent(s). The substituent of the heterocyclic group is exemplified by oxo group, hydroxyl group, an alkanoyl group or an alkyl group. The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc. The substituent of the optionally substituted heterocyclic group of the above-mentioned (ii) is exemplified by an alkanoyl group optionally substituted by hydroxyl group, oxo group or hydroxyl group. The heterocyclic group is exemplified by a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s). The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc.
The heterocyclic group of the above-mentioned (V) is exemplified by a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s). The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, tetrazolyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, tetrahydropyranyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc.
The substituent of the optionally substituted cycloalkyl group of the above-mentioned (2) is exemplified by an optionally substituted hydroxyl group, an alkyl group, cyano group, a halogen atom, etc. The cycloalkyl group may have 1 or 2 substituent(s). The substituent(s) for the optionally substituted hydroxyl group is exemplified by an alkyl group optionally substituted by hydroxyl group, etc.
The substituent of the optionally substituted aryl group of the above-mentioned (3) is exemplified by hydroxyl group, an alkyl group, cyano group, a halogen atom, etc. The aryl group is exemplified by phenyl group, naphthyl group, anthracenyl group or phenanthrenyl group.
The substituent of the optionally substituted heterocyclic group of the above-mentioned (4) is exemplified by
The heterocyclic group may have 1 to 2 substituent(s) which may be the same or different from each other. The heterocyclic group is exemplified by a heteromonocyclic group having 1 to 4 atoms selected from sulfur atom, nitrogen atom and oxygen atom as hetero atom(s), and a saturated heteromonocyclic group is preferably used. The heteromonocyclic group is exemplified by pyrazinyl group, piperidinyl group, piperazinyl group, pyridyl group, tetrazolidyl group, pyrrolidinyl group, imidazolidinyl group, morpholinyl group, thiomorpholinyl group, tetrahydropyranyl group, tetrahydrothiopyranyl group, azetidinyl group or thietanyl group. Of these, pyrazinyl group, piperidinyl group, piperazinyl group, pyrrolidinyl group, morpholinyl group, thiomorpholinyl group, tetrahydropyranyl group, tetrahydrothiopyranyl group or azetidinyl group is preferred.
The substituent of the optionally substituted alkanoyl group of the above-mentioned (II) is exemplified by hydroxyl group, etc.
The substituent of the optionally substituted alkyl group of the above-mentioned (III) is exemplified by hydroxyl group or a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s), and the heterocyclic group may have a substituent(s). The substituent of the heterocyclic group is exemplified by oxo group, hydroxyl group, an alkanoyl group or an alkyl group. The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc.
The substituent(s) for the optionally substituted hydroxyl group of the above-mentioned (IV) is exemplified by an alkyl group optionally substituted by hydroxyl group, etc.
The substituent of the optionally substituted amino group of the above-mentioned (5) is exemplified by an alkyl group optionally substituted by hydroxyl group, a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s), and the heterocyclic group may have a substituent(s). The substituent of the heterocyclic group is exemplified by oxo group, hydroxyl group, an alkanoyl group or an alkyl group. The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc. The amino group may have 1 to 2 substituent(s).
The substituent of the optionally substituted alkoxy group of the above-mentioned (6) is exemplified by hydroxyl group.
In the present invention, the substituent of the substituted sulfonyl group of R1 is an optionally substituted alkyl group. The substituent of the optionally substituted alkyl group is exemplified by hydroxyl group or an alkanoyloxy group.
In the present invention, the substituent of the optionally substituted heterocyclic group of R1 is exemplified by
The heterocyclic group may have 1 to 2 substituent(s) which may be the same or different from each other. The heterocyclic group is exemplified by a heterocyclic group having 1 to 4 atoms selected from nitrogen atom, oxygen atom and sulfur atom as hetero atom(s). The heterocyclic group is exemplified by a saturated or unsaturated monocyclic or bicyclic heteroaromatic group, and may include, for example, thienyl group, furyl group, tetrahydrofuryl group, pyranyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, isothiazolyl group, isoxazolyl group, pyridyl group, pyrazinyl group, pyrimidinyl group, pyridazinyl group, azetidinyl group, thietanyl group, pyrrolidinyl group, pyrrolinyl group, imidazolidinyl group, imidazolinyl group, pyrazolidinyl group, pyrazolinyl group, piperidinyl group, piperazinyl group, morpholinyl group, thiomorpholinyl group, tetrahydropyranyl group, tetrahydrothiopyranyl group, benzothienyl group, benzofuryl group, isobenzofuranyl group, chromenyl group, indolyl group, isoindolyl group, indazolyl group, purinyl group, quinolizinyl group, naphthyridinyl group, quinoxalinyl group, cinnolinyl group, quinolyl group, isoquinolyl group, benzothiazolyl group, benzisothiazolyl group, quinazolinyl group, phthalazinyl group, benzoxazolyl group, benzimidazolyl group, pteridinyl group, pyridopyrimidinyl group, isochromanyl group, chromanyl group, indolinyl group, isoindolinyl group, tetrahydroquinolyl group, tetrahydroisoquinolyl group, tetrahydroquinoxalinyl group, dihydrophthalazinyl group, etc. Of these heterocyclic groups, piperidinyl group, tetrahydropyranyl group, tetrahydrothiopyranyl group, azetidinyl group or thietanyl group is suitably used.
The substituent of the optionally substituted alkanoyl group of the above-mentioned (I) is exemplified by hydroxyl group, an alkoxy group, a phenylalkoxy group, an alkanoylamino group, an alkylsulfonyl group, an alkanoyl group, aminocarbonyl group, etc.
The substituent of the substituted carbonyl group of the above-mentioned (II) is exemplified by phenyl group, a hydroxycycloalkyl group, a dialkylamino group, a hydroxyalkylamino group, amino group, tetrahydrofuryl group, an alkanoyl group, aminocarbonyl group, or a pyrrolidinyl group which is optionally substituted by 1 or 2 substituent(s) selected by oxo group and an alkyl group, etc.
The substituent of the optionally substituted alkylsulfonyl group of the above-mentioned (III) is exemplified by hydroxyl group, amino group, heterocyclic group, etc.
The substituent of the optionally substituted alkyl group of the above-mentioned (IV) is exemplified by an alkylsulfonyl group, carboxyl group, etc.
In the present invention, R2 is hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom.
In the present invention, the substituent of the optionally substituted hydroxyl group of R2 is exemplified by an alkyl group optionally substituted by hydroxyl group.
In the present invention, the substituent of the optionally substituted amino group of R2 is exemplified by an alkyl group optionally substituted by hydroxyl group.
In the present invention, the substituent of the optionally substituted alkyl group of R2 is an alkoxy group optionally substituted by hydroxyl group, or hydroxyl group.
In the present invention, the substituent of the substituted carbonyl group of R2 is exemplified by hydroxyl group, an alkoxy group optionally substituted by hydroxyl group or an alkylamino group optionally substituted by hydroxyl group.
In the present invention, Z is exemplified by oxygen atom or a group represented by —N(R3)—.
In the present invention, R3 is exemplified by hydrogen atom or an optionally substituted alkyl group. The substituent of the optionally substituted alkyl group of R3 is exemplified by hydroxyl group, an alkanoyl group, a halogen atom, an alkoxy group or an alkylamino group.
In the present invention, R4a and R4b may be the same or different from each other, and are each exemplified by hydrogen atom, an optionally substituted alkyl group, or may be bonded to each other at the both ends to form an alkylene group. The substituent of the optionally substituted alkyl group is exemplified by hydroxyl group, etc.
As the preferred compound of the present invention, a compound where R1 is an optionally substituted alkyl group is mentioned. The substituent of the alkyl group is preferably exemplified by an alkoxy group, a halogen atom, a dialkylaminocarbonyl group, oxopyridyl group, dioxopyrrolidinyl group, morpholinocarbonyl group, hydroxyl group, an alkoxycarbonyl group or a hydroxyalkylaminocarbonyloxy group, more preferably an alkoxy group, a halogen atom, a dialkylaminocarbonyl group, oxopyridyl group or dioxopyrrolidinyl group.
As the preferred compound of the present invention, a compound where R1 is a substituted carbonyl group is mentioned. The preferred substituent of the carbonyl group is exemplified by an alkyl group optionally substituted by hydroxyl group, an alkanoylamino group optionally substituted by an alkyl group, an alkylsulfonyl group, tetrahydropyranyl group, tetrazolyl group or nitro group; an alkoxy group; a hydroxyalkylamino group; a cycloalkyl group substituted by 1 or 2 substituents selected from hydroxyl group and an alkyl group; piperidinyl group substituted by 1 or 2 substituents selected from an alkanoyl group, an alkoxycarbonyl group, oxo group and an alkyl group; tetrahydropyranyl group; tetrahydrothiopyranyl group the sulfur atom of which is substituted by 2 oxo groups; pyrrolidinyl group substituted by 1 or 2 substituents selected from an alkanoyl group, hydroxyl group, an alkyl group and oxo group; pyrazinyl group; morpholino group; thiomorpholino group the sulfur atom of which is optionally substituted by oxo group; or piperazine group substituted by an alkyl group which may be optionally substituted by hydroxy group, or by an alkanoyl group.
As the preferred compound of the present invention, a compound where R1 is a substituted sulfonyl group is mentioned. The substituent of the sulfonyl group is preferably exemplified by an alkyl group.
As the preferred compound of the present invention, a compound where R1 is an optionally substituted heterocyclic group is mentioned. The heterocyclic group is preferably exemplified by piperidinyl group, tetrahydropyranyl group, tetrahydrothiopyranyl group, thietanyl group or azetidinyl group. Also, the substituent of the heterocyclic group is preferably exemplified by an alkanoyl group, a hydroxyalkanoyl group, a dihydroxyalkanoyl group, an alkoxyalkanoyl group, an alkanoylaminoalkanoyl group, an alkylsulfonylalkanoyl group, an alkanoylalkanoyl group, an aminocarbonylalkanoyl group, an alkoxycarbonyl group, an alkylsulfonyl group, oxo group, a phenylalkoxycarbonyl group, a dialkylcarbonyl group, a hydroxycycloalkyl group, a hydroxyalkylaminocarbonyl group, aminocarbonyl group, tetrahydrofurylcarbonyl group, an alkyldiketonyl group, an aminodiketonyl group, an alkylsulfonylalkyl group, an carboxyalkyl group, or a pyrrolidinylcarbonyl group which is optionally substituted by substituent(s) selected by oxo group and an alkyl group, etc. The heterocyclic group may have 1 or 2 substituents which may be the same or different from each other.
As the compound [I] of the present invention, a compound where Ring A is a benzene ring represented by the formula:
Ring B is a benzene ring represented by the formula:
A1 is hydrogen atom, a halogen atom, an alkyl group or an alkoxy group, A2 is hydrogen atom or a halogen atom, B1 is hydrogen atom, an alkyl group, a halogen atom, cyano group, an alkoxy group or a trihalogenoalkyl group, B2 is hydrogen atom, an alkyl group, a halogen atom, cyano group, an alkoxy group or a trihalogenoalkyl group, R1 is hydrogen atom; an alkyl group substituted by an alkoxy group, a halogen atom, a dialkylaminocarbonyl group, oxopyridyl group, dioxopyrrolidinyl group, morpholinocarbonyl group, hydroxyl group, an alkoxycarbonyl group, morpholinoaminocarbonyl group, a hydroxyalkylaminocarbonyloxy group or an alkylpiperazinocarbonyl group; a hydroxycycloalkyl group; carboxyl group; an alkanoyl group substituted by hydroxyl group, an alkanoylamino group optionally substituted by an alkyl group, an alkylsulfonyl group, tetrahydropyranyl group, tetrazolyl group or nitro group; an alkoxycarbonyl group optionally substituted by hydroxyl group; pyrimidinylaminocarbonyl group; an alkylaminocarbonyl group the alkyl group portion of which is optionally substituted by hydroxyl group or cyano group; a di(hydroxyalkyl)aminocarbonyl group; a cycloalkylcarbonyl group substituted by 1 or 2 groups selected from hydroxyl group and an alkyl group; pyridylaminocarbonyl group the pyridyl group portion of which is substituted by hydroxyl group; an aminocarbonyl group substituted by an alkylpyrido group and an alkyl group; piperidinylcarbonyl group substituted by 1 or 2 groups selected from an alkanoyl group, an alkoxycarbonyl group, oxo group and an alkyl group; tetrahydropyranylcarbonyl group; tetrahydrothiopyranylcarbonyl group the sulfur atom of which is substituted by 2 oxo groups; piperazinocarbonyl group substituted by oxo group, an alkyl group optionally substituted by hydroxyl group, pyrimidinyl group, an alkylsulfonyl group or an alkanoyl group; pyradinylcarbonyl group; morpholinocarbonyl group; thiomorpholinocarbonyl group the sulfur atom of which is optionally substituted by oxo group; pyrrolidinylcarbonyl group substituted by 1 or 2 groups selected from an alkanoyl group, hydroxyl group, an alkyl group and oxo group; an alkylsulfonyl group optionally substituted by hydroxyl group or an alkanoyloxy group; piperidinyl group substituted by an alkanoyl group, an alkoxycarbonyl group or an alkylsulfonyl group; tetrahydropyranyl group; tetrahydrothiopyranyl group the sulfur atom of which is optionally substituted by 1 or 2 oxo groups; thietanyl group the sulfur atom of which is optionally substituted by 2 oxo groups; or azetidinyl group optionally substituted by a phenylalkoxycarbonyl group, an alkanoyl group, a hydroxyalkanoyl group, an alkoxycarbonyl group, a dihydroxyalkanoyl group, an alkoxyalkanoyl group, an alkanoylaminoalkanoyl group, an alkylsulfonylalkanoyl group, an alkanoylalkanoyl group, an aminocarbonylalkanoyl group, a hydroxyalkoxycarbonyl group, an alkylsulfonyl group, a dialkylaminocarbonyl group, a hydroxyalkylcarbonyl group, aminocarbonyl group, a hydroxycycloalkylcarbonyl group, tetrahydrofurylcarbonyl group, an alkyldiketonyl group, an aminodiketonyl group, an alkylsulfonylalkyl group, a carboxylalkyl group or a pyrrolidinyl group which is optionally substituted by 1 or 2 substituent(s) selected by oxo group and an alkyl group, R2 is hydrogen atom, Z is oxygen atom or a group represented by —N(R3)—, R3 is an alkyl group optionally substituted by hydroxyl group, R4a is hydrogen atom or an alkyl group optionally substituted by hydroxyl group, and R4b is hydrogen atom or an alkyl group optionally substituted by hydroxyl group is mentioned.
Of these, preferred are compounds wherein Ring A is a benzene ring represented by the formula:
Ring B is a benzene ring represented by the formula:
A1 is hydrogen atom, an alkyl group or a halogen atom, A2 is hydrogen atom or a halogen atom, B1 is a trihalogenomethyl group, a halogen atom or an alkyl group, B2 is a trihalogenomethyl group, a halogen atom or an alkyl group, R1 is hydrogen atom; an alkyl group substituted by an alkoxy group, a halogen atom, a dialkylaminocarbonyl group, oxopyridyl group or dioxopyrrolidinyl group; an alkanoyl group substituted by hydroxyl group, an alkanoylamino group optionally substituted by an alkyl group, an alkylsulfonyl group, tetrahydropyranyl group, tetrazolyl group or nitro group; an alkoxycarbonyl group; a hydroxyalkylaminocarbonyl group; a cycloalkylcarbonyl group substituted by 1 or 2 groups selected from hydroxyl group and an alkyl group; piperidinylcarbonyl group substituted by 1 or 2 groups selected from an alkanoyl group, an alkoxycarbonyl group, oxo group and an alkyl group; tetrahydropyranylcarbonyl group; tetrahydrothiopyranylcarbonyl group the sulfur atom of which is substituted by 2 oxo groups; pyrrolidinylcarbonyl group substituted by 1 or 2 groups selected from an alkanoyl group, hydroxyl group, an alkyl group and oxo group; pyradinylcarbonyl group; morpholinocarbonyl group; thiomorpholinocarbonyl group the sulfur atom of which is optionally substituted by oxo group; piperazinocarbonyl group substituted by an alkyl group optionally substituted by hydroxyl group, or by an alkanoyl group; piperidinyl group substituted by an alkanoyl group, an alkoxycarbonyl group or an alkylsulfonyl group; tetrahydropyranyl group; tetrahydrothiopyranyl group the sulfur atom of which is optionally substituted by 1 or 2 oxo groups; thietanyl group the sulfur atom of which is optionally substituted by 2 oxo groups; or azetidinyl group optionally substituted by a phenylalkoxycarbonyl group, an alkanoyl group, a hydroxyalkanoyl group, a dihydroxyalkanoyl group, an alkoxyalkanoyl group, an alkanoylaminoalkanoyl group, an alkylsulfonylalkanoyl group, an alkanoylalkanoyl group, an aminocarbonylalkanoyl group, an alkoxycarbonyl group, a hydroxyalkoxycarbonyl group, an alkylsulfonyl group, a dialkylaminocarbonyl group, a hydroxyalkylaminocarbonyl group, aminocarbonyl group, an hydroxycycloalkylcarbonyl group, tetrahydrofurylcarbonyl group, an alkyldiketonyl group, an aminodiketonyl group, an alkylsulfonylalkyl group, a carboxylalkyl group or a pyrrolidinyl group which is optionally substituted by 1 or 2 substituent(s) selected by oxo group and an alkyl group, R2 is hydrogen atom, Z is a group represented by —N(R3)—, R3 is an alkyl group, R4a is hydrogen atom or an alkyl group, and R4b is hydrogen atom or an alkyl group.
Moreover, preferred are compounds wherein Ring A is a benzene ring represented by the formula:
Ring B is a benzene ring represented by the formula:
A1 is hydrogen atom or an alkyl group, A2 is a halogen atom, B1 is a trihalogenomethyl group, B2 is a trihalogenomethyl group, R1 is an alkanoylaminoalkanoyl group; piperidinylcarbonyl group optionally substituted by 1 or 2 group(s) selected from an alkanoyl group, oxo group and an alkyl group; piperidinyl group substituted by an alkanoyl group; tetrahydrothiopyranyl group the sulfur atom of which is di-substituted by oxo group; thietanyl group the sulfur atom of which is optionally substituted by 2 oxo groups; or azetidinyl group substituted by an alkanoyl group optionally substituted by hydroxyl group, an alkoxycarbonyl group, an alkylsulfonyl group or dialkylaminocarbonyl group, R2 is hydrogen atom, Z is a group represented by the formula —N(R3)—, R3 is an alkyl group, R4a is hydrogen atom or an alkyl group, R4b is hydrogen atom or an alkyl group.
Furthermore, in the compounds of the present invention, preferred compounds are a compound selected from the following (A) to (S) or a pharmaceutically acceptable salt thereof.
The compound [I] of the present invention can be used for a pharmaceutical use either in a free form or in form of a pharmaceutically acceptable salt.
As the pharmaceutically acceptable salt of the compound [I] of the present invention, there may be mentioned, for example, an inorganic acid salt such as hydrochloride, sulfate, phosphate and hydrobromide; and an organic acid salt such as acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, tosylate, maleate,.succinate and tartarate.
Further, the compound [I] of the present invention or a pharmaceutically acceptable salt thereof includes any of its internal salts, solvates and hydrates, etc.
Although an optical isomer based on an asymmetric carbon can be present in the compound [I] of the present invention, the present invention includes any of these optical isomers and the mixture thereof.
The compound [I] or a pharmaceutically acceptable salt thereof of the present invention has an excellent tachykinin receptor antagonistic action, particularly an SP receptor antagonistic action, whereby it is useful as a safe medicament for prophylaxis and treatment for inflammation or allergic diseases (for example, atopic dermatitis, dermatitis, herpes, psoriasis, asthma, bronchitis, expectoration, rhinitis, rheumatoid arthritis, osteoarthritis, osteoporosis, multiple sclerosis, conjunctivitis, ophthalmia, cystitis, etc.), pain, migraine, neuralgia, itchiness, cough, and further central nervous system diseases (for example, schizophrenia, Parkinson's disease, depression, uneasiness, psychosomatic disorder, morphine dependence, dementia (for example, Alzheimer's disease, etc.), etc.), digestive organs disease (for example, irritable bowel syndrome, ulcerative colitis, Crohn's disease, disorder (for example, gastritis, gastric ulcer, etc.) related to urease-positive Spirillum (for example, helicobacter pylori, etc.), etc.), nausea, emesis, urinary disorder (for example, pollakiurea, urinary incontinence, etc.), circulatory disease (for example, angina pectoris, hypertension, cardiac failure, thrombosis, etc.) and immune disorder, etc. in mammals (for example, mouse, guinea pig, Mongolian gerbil, ferret, rat, hamster, rabbit, cat, dog, bovine, sheep, monkey, human, etc.). Particularly, since compound [I] or a pharmaceutically acceptable salt thereof which is an active ingredient of the present invention has a high penetration to the brain and has a low toxicity (high safety), showing almost no side effect, it is useful as a therapeutic or prophylactic agent for central nervous system diseases such as emesis, depression and so forth, or urinary disorder such as pollakiuria, etc.
Measurements on the compound of the present invention or a pharmaceutically acceptable salt thereof can be carried out, according to the method described in European Journal of Pharmacology, vol. 254, pages 221-227 (1994) with respect to a neurokinin-1 receptor binding action, and according to the method described in European Journal of Pharmacology, vol. 265, pages 179-183 (1994) with respect to neurokinin-1 receptor antagonstic action, further according to the method described in Journal of Urology, vol. 155, No. 1, pages 355-360 (1996) with regard to an inhibitory action on pollakiuria.
The compound [I] or a pharmaceutically acceptable salt thereof of the present invention can be administered orally or parenterally, and it can be formulated into a suitable preparation, using a conventionally used pharmaceutical carrier for an oral or parenteral administration. As such a pharmaceutical carrier, there may be mentioned, for example, a binder (syrup, Gum Arabic, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone, etc.), an excipient (lactose, sugar, corn starch, potassium phosphate, sorbitol, glycine, etc.), a lubricant (magnesium stearate, talc, polyethylene glycol, silica, etc.), a disintegrator (potato starch, etc.) and a wetting agent (anhydrous lauryl sodium sulfate, etc.), and the like.
Also, when these pharmaceutical preparations are administered orally, they may be a solid preparation such as tablets, granules, capsules and powders, or a liquid preparation such as solution, suspension and emulsion. On the other hand, when they are administered parenterally, for example, they can be administered as an injection solution or an infusion solution, using distilled water for injection, physiological saline, aqueous glucose solution, etc., or they may be administered as a suppository, and the like.
A dose of the compound [I] or a pharmaceutically acceptable salt thereof of the present invention may vary depending on an administration method, an age, a body weight or a condition of a patient, etc., and, for example, in case of oral administration, it is usually administered in a dose of 0.1 to 20 mg/kg per day, and particularly preferably 0.1 to 10 mg/kg per day, and in case of parenteral administration, usually in a dose of 0.01 to 10 mg/kg per day, particularly preferably 0.01 to 1 mg/kg per day.
[Method A]
The compound of the formula [I]:
This [Method A] can be carried out as mentioned below.
[Method A]
The reaction of Compound [II] with Compound [III] can be carried out in a solvent in the presence of a condensing agent; or reacting Compound [II] with a reactive derivative (acid halide, acid anhydride, active amide, active ester, mixed acid anhydride, etc.) of Compound [III] in a solvent in the presence or absence of a base and in the presence or absence of a condensing agent, to prepare a target compound. As the base, organic bases such as pyridine, 4-dimethylaminopyridine, N-methylmorpholine, triethylamine, N,N-dimethylaniline, N,N-diethylaniline, 1,8-diazabicyclo-[5.4.0]undec-7-ene, etc., inorganic bases such as sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, etc. can be used. As the condensing agent, 1,1′-carbonyldiimidazole, 1,3-dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, propanephosphonic acid anhydride, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluoro phosphorus, etc. can be used. As the solvent, any solvent can be used as long as it does not exert any bad effect on the reaction, and, for example, N,N-dimethylformamide, dichloromethane, chloroform, tetrahydrofuran, dioxane, ethyl acetate, 1,3-dimethyl-2-imidazolidinone, etc. can be used. This reaction suitably proceeds, for example, at −20° C. to 60° C., particularly preferably at 5° C. to 50° C. As the active ester of Compound [III], an ester with N-hydroxysuccinic imide, N-hydroxyphthalimide, 1-hydroxybenzotriazole or p-nitrophenol can be used. As the acid halide of Compound [III], an acid chloride, an acid bromide, etc., can be suitably used. Also, as the active amide of Compound [III], an amide with imidazole, etc. can be used.
The objective Compound [I] of the present invention can be also prepared by converting the group R1 of the compound obtained as mentioned above into the other substituent. Such a converting method of the substituent can be suitably selected depending on the kinds of the substituents to be converted, for example, it can be carried out by the following (Method a) to (Method i).
The solvent to be used in the reactions described in the above-mentioned (Method a) to (Method i) is not specifically limited so long as it does not inhibit the reaction, and, for example, dioxane, ethylene glycol dimethyl ether, dimethylacetamide, dimethylformamide, hexamethylphosphoramide, benzene, tetrahydrofuran, toluene, ethyl acetate, alcohol, dichloromethane, chloroform, carbon tetrachloride, 1,3-dimethyl-2-imidazolidine, acetic acid, diethyl ether, methoxyethane, dimethylsulfoxide, acetonitrile, water or a mixed solvent of the above solvents can be used by optionally selecting them.
Incidentally, of the starting Compound [II] of the present invention, the following Compound [II-a] and Compound [II-b] are novel compounds, and can be prepared, for example, by the following chemical reaction formulae.
That is, the pyridine compound [IV] is subjected to condensation with aniline to give Compound [V], then, subjecting to halogenation to give Compound [VI], and the aniline is eliminated to give Compound [VII]. Also, Compound [IX] is obtained by esterifying the carboxyl group of Compound [VII], subjecting Compound [VIII] to carbonyl insertion, or esterifying the acyl group of Compound [IV] and then to haloganate. The obtained Compound [IX] and Compound [X] are coupled or Compound [VI] and Compound [X] are coupled to give Compound [XI], and the aniline is eliminated to give Compound [XII], the resulting Compound [XII] is subjected to reduction, then, a substituent of the amino group is introduced to give Compound [XIII]. An ester group of the resulting Compound [XIII] is converted to a carboxyl group to give Compound [XIV]. Moreover, the carboxyl group of the resulting Compound [XIV] is subjected to rearrangement, etc., to give Compound [II-a], or Compound [XIII] or Compound [XIV] is oxidized and then hydrolyzed to give Compound [II-b].
Also, Compound [II-a] can be converted to the following Compound [II-c] according to the following chemical reaction formula.
That is, Compound [XV] is obtained by substituting the amino group of Compound [II-a] with R3, and then, Compound [II-c] is obtained by removing the protective group for the amino group.
Compound [II] (for example, Compound [II-a], Compound [II-b] or Compound [II-c], etc.) has an asymmetric carbon, and optical isomers exist based on the asymmetric carbon. For example, when cis-isomer and trans-isomer are obtained as a mixture, the respective cis-isomer and trans isomer can be obtained separately by a conventional manner such as silica gel chromatography, etc. Also, optical isomers of Compound [II] can be obtained, for example, by optically resolving racemic mixtures of Compound [II], or racemic mixtures of Compound [XIII] where R1 is hydrogen atom or racemic mixtures of Compound [II] are optically resolved according to a conventional manner to give a corresponding optically active compound, and then, the resulting compound is applied to the above-mentioned reaction.
In the case of a compound wherein R1 of Compound [XIII] is hydrogen atom, optical resolution can be carried out, for example, by acting Compound [XIII] with N-acyl-optically active amino acid, N-sulfonyl-optically active amino acid or optically active carboxylic acid, and separating and collecting one of the diastereomer salts utilizing the differences in solubility between two kinds of the formed diastereomer salts. The acyl group of the N-acyl-optically active amino acid can be exemplified by, for example, acetyl group, propionyl group, tosyl group or benzyloxycarbonyl group, and the optically active amino acid can be exemplified by, for example, L-phenylalanine, L-leucine, L-glutamine, L-methionine, L-valine, L-threonine, D-phenylalanine or D-phenylglycine. Also, the optically active carboxylic acid is exemplified by mandelic acid, malic acid or tartaric acid derivatives. The tartaric acid derivatives are exemplified by dibenzoyl-L-tartaric acid, di-p-toluoyl-L-tartaric acid, dibenzoyl-D-tartaric acid, di-p-toluoyl-D-tartaric acid, etc.
Also, in the case of Compound [XIV], optical resolution can be carried out by, for example, acting Compound [XIV] with O-alkyl-optically active amino acid or an optically active amine derivative, and separating and collecting one of the diastereomer salts utilizing the differences in solubility between two kinds of the formed diastereomer salts. The optically active amino acid can be exemplified by, for example, L-phenylalanine, L-leucine, L-glutamine, L-methionine, L-valine, L-threonine, D-phenylalanine or D-phenylglycine. The alkyl group of the O-alkyl-optically active amino acid can be exemplified by methyl group, ethyl group, etc. The optically active amine derivative can be exemplified by brucine, quinidine, (S)-α-phenethylamine, (R)-β-phenethylamine, (R)-(−)-1-cyclohexylethylamine, (S)-(+)-1-cyclohexylethylamine, etc.
Further, in preparation of the objective compounds or the starting materials of the present invention, when the starting materials or the intermediates have a functional group, a suitable protecting group can be introduced to each of the functional group by a conventional method, besides the above described method, and if they are not necessary, these protecting groups may be suitably removed.
For example, in the present specification, as the protective group for the amino group, a protective group to be generally used for protecting the amino group for applying the same to a reaction, and it can be specifically exemplified by, for example, an alkoxycarbonyl group such as tert-butoxycarbonyl group, an arylalkoxycarbonyl group such as benzyloxycarbonyl group, etc.
In the present specification, the alkyl group means, for example, a straight or branched alkyl group having 1 to 6 carbon atoms such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, isopentyl group, etc., preferably those having 1 to 4 carbon atoms. The alkenyl group means, for example, a straight or branched alkenyl group having 2 to 7 carbon atoms such as vinyl group, allyl group, propenyl group, isopropenyl group, etc., preferably those having 2 to 4 carbon atoms. The alkoxy group means a straight or branched alkoxy group having 1 to 6 carbon atoms such as methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, etc., preferably those having 1 to 4 carbon atoms. The alkanoyl group means a straight or branched alkanoyl group having 1 to 6 carbon atoms such as formyl group, acetyl group, propionyl group, butyryl group, valeryl group, tert-butylcarbonyl group, etc., preferably those having 1 to 4 carbon atoms. The alkylene group means, for example, a straight or branched alkylene group having 1 to 6 carbon atoms such as methylene group, ethylene group, propylene group, butylene group, pentylene group, hexylene group, etc., preferably those having 1 to 4 carbon atoms. The cycloalkyl group means, for example, a cycloalkyl group having 3 to 8 carbon atoms such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, etc., preferably those having 3 to 6 carbon atoms. Further, the halogen atom is exemplified by chlorine atom, bromine atom, fluorine atom and iodine atom. The aryl group is exemplified by an unsaturated hydrocarbon cyclic group such as phenyl group, naphthyl group, phenanthryl group, etc.
To 27 ml of a tetrahydrofuran solution containing 1.42 g of 2-(3,5-bistrifluoromethylphenyl)-2-methylpropionic acid were added a catalytic amount of N,N-dimethylformamide and 1.07 g of thionyl chloride, the resulting mixture was stirred under reflux for 2 hours, and the reaction mixture was concentrated under reduced pressure. To 10 ml of dichloromethane solution containing 1.45 g of (3S,4S)-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-(N-methylamino)piperidine cooled to 0° C. were added 0.51 g of triethylamine and 3 ml of dichloromethane solution containing the above-mentioned residue obtained by concentration under reduced pressure, and the resulting mixture was stirred at 0° C. for 1 hour. To the reaction mixture were added dichloromethane and water, and the mixture was separated, the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=19:1→4:1) to give 2.12 g of (3S,4S)-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 1.
The corresponding starting materials were used and treated in the same manner as in Example 1, to give compounds shown in the following Table 1 and Table 2.
To 20 ml of a tetrahydrofuran solution containing 0.95 g of 2-(3,5-bistrifluoromethylphenyl)propionic acid were added a catalytic amount of N,N-dimethylformamide and 0.80 g of thionyl chloride, the resulting mixture was stirred under reflux for 3 hours, and the reaction mixture was concentrated under reduced pressure. To 6 ml of a dichloromethane solution containing 0.97 g of (3S,4S)-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-(N-methylamino)piperidine cooled to 0° C. were added 0.36 g of triethylamine and 1 ml of a dichloromethane solution containing the above-mentioned residue obtained by concentration under reduced pressure, and the resulting mixture was stirred at 0° C. for 3 hours. To the reaction mixture were added chloroform and water, and the mixture was separated, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:ethyl acetate=9:1→2:1) to give (a) 0.76 g of (3S,4S)-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-{(R)-N-methyl-2-(3,5-bistrifluoromethylphenyl)propionylamino}-piperidine, and (b) 0.82 g of (3S,4S)-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-{(S)-N-methyl-2-(3,5-bistrifluoromethylphenyl}propionylaminolpiperidine shown in the following Table 3.
The corresponding starting materials were used and treated in the same manner as in Example 6, to give compounds shown in the following Table 3.
15 ml of an N,N-dimethylformamide solution containing 484 mg of trans-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-(N-methylamino)piperidine, 449 mg of 3,5-bistrifluoromethylphenylacetic acid, 253 mg of 1-hydroxybenzotriazole monohydrate, and 316 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride was stirred at room temperature for 16 hours. To the reaction mixture were added ethyl acetate and semi-saturated brine, and the mixture was separated, and the organic layer was washed successively with semi-saturated brine and an aqueous sodium hydrogen carbonate solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the obtained residue was purified by NH silica gel column chromatography (n-hexane:ethyl acetate=19:1→2:1) to give 380 mg of trans-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-(3,5-bistrifluoromethylphenyl)acetylamino}piperidine shown in the following Table 4.
To 8 ml of an ethyl acetate solution containing 2.12 g of (3S,4S)-l-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine was added 26 ml of 4M ethyl acetate solution of hydrochloric acid, and the mixture was stirred at room temperature for 1 hour, and concentrated under reduced pressure. To the residue were added ethyl acetate and water, and the aqueous layer was made basic by using an aqueous sodium carbonate solution and aqueous ammonia and the solutions were separated. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 1.39 g of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 4.
The corresponding starting materials were used and treated in the same manner as in Example 9, to give compounds shown in the following Table 4 to Table 6.
3.3 ml of an N,N-dimethylformamide solution containing 127 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine, 37 mg of β-hydroxyisovaleric acid, 48 mg of 1-hydroxybenzotriazole monohydrate and 60 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride was stirred at 40° C. for 16 hours. To the reaction mixture were added ethyl acetate and semi-saturated brine, and the mixture was separated, and then, the organic layer was washed successively with semi-saturated brine and a saturated aqueous sodium hydrogen carbonate solution. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by NH thin-layer silica gel column chromatography (chloroform:ethyl acetate=20:1) to give 148 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-1-(3-hydroxy-3-methylbutyryl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 7.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 7 to Table 17.
To 1.5 ml of an N,N-dimethylformamide solution containing 30 mg of the compound obtained in Example 26 cooled to 0° C. was added 2 mg of sodium hydride, the mixture was stirred at 0° C. for 30 minutes, 8 mg of methyl iodide was then added to the mixture and the resulting mixture was stirred at room temperature for 2 hours. To the reaction mixture were added ethyl acetate and semi-saturated brine, the mixture was separated, and the organic layer was washed with semi-saturated brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by basic thin layer silica gel chromatography (chloroform:n-hexane: ethyl acetate=1:1:1) to give 11 mg of (3S,4S)-1-(N-acetyl-N-methyl-amino)acetyl-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 18.
The corresponding starting materials were used and treated in the same manner as in Example 75, to give compounds shown in the following Table 18 and Table 19.
To 3.3 ml of a dichloromethane solution containing 127 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine and 42 mg of 1-acetyl-4-piperidone was added 1 drop of acetic acid, the mixture was stirred at room temperature for 1 hour. Then, 106 mg of sodium triacetoxyborohydride was added to the mixture, and the resulting mixture was stirred at 40° C. for 16 hours. To the reaction mixture were added chloroform and a saturated sodium hydrogen carbonate solution and the mixture was separated. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by NH thin-layer silica gel column chromatography (chloroform:ethyl acetate=20:1) to give 86 mg of (3S,4S)-1-(1-acetyl-piperidin-4-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 20.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 20.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 21.
The corresponding starting materials were used and treated in the same manner as in Example 93, to give compound shown in the following Table 21.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 22 and Table 23.
To 1.5 ml of an N,N-dimethylformamide solution containing 35 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylaminolpiperidine were added 14 mg of triethylamine and 15 mg of 2-bromoethylmethyl ether, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture were added ethyl acetate and semi-saturated brine, the mixture was separated, and the organic layer was washed with semi-saturated brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by thin layer silica gel chromatography (chloroform:methanol=19:1) to give 22 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-1-(2-methoxyethyl)-4-1N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}-piperidine shown in the following Table 24.
The corresponding starting materials were used and treated in the same manner as in Example 101, to give a compound shown in the following Table 24.
1.5 ml of an acetonitrile solution containing 35 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine, 13 mg of 2-chloro-N,N′-dimethylacetamide, and 21 mg of potassium carbonate was stirred under reflux for 16 hours. To the reaction mixture were added ethyl acetate and water, and the mixture was separated. The obtained organic layer was washed successively with a saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by basic thin layer silica gel chromatography (hexane:ethyl acetate=1:1) to give 31 mg of (3S,4S)-1-(1,1-dimethylcarbamoylmethyl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 24.
The corresponding starting materials were used and treated in the same manner as in Example 103, to give compounds shown in the following Table 24.
To 1.5 ml of an ethanol solution containing 35 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine was added 10 mg of N,N-dimethyl acrylamide, and the mixture was stirred under reflux for 16 hours. To the reaction mixture were added ethyl acetate and semi-saturated brine, and the mixture was separated. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by NH thin layer silica gel chromatography (hexane:ethyl acetate=1:2) to give 30 mg of (3S,4S)-1-(2,2-dimethylcarbamoylethyl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 24.
To 1.5 ml of a dichloromethane solution containing 20 mg of N-(2-hydroxyethyl)succinimide was added 21 mg of triethylamine, and the mixture was cooled to 0° C. To the mixture was added 24 mg of methanesulfonyl chloride, and the resulting mixture was stirred at room temperature for 16 hours, and then, the reaction mixture was concentrated under reduced pressure. A mixture comprising 35 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine, 31 mg of potassium carbonate, and 2 ml of an acetonitrile solution containing the above-mentioned residue concentrated under reduced pressure was stirred under reflux for 16 hours. To the reaction mixture were added ethyl acetate and water, the mixture was separated, and the obtained organic layer was washed successively with a saturated aqueous sodium hydrogen carbonate solution and saturated brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by NH thin layer silica gel chromatography (hexane:ethyl acetate=1:1) to give 16 mg of (3S,4S)-1-{2-(2,5-dioxopyrrolidin-1-yl)ethyl}-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 24.
The corresponding starting materials were used and treated in the same manner as in Example 103, to give compounds shown in the following Table 25.
The corresponding starting materials were used and treated in the same manner as in Example 106, to give a compound shown in the following Table 25.
To 2 ml of a dichloromethane solution containing 35 mg of (3S,4S)-1-(azetidin-3-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine cooled to 0° C. were added 8 mg of triethylamine and 6 mg of acetyl chloride, and the mixture was stirred at 0° C. for 2 hours. To the reaction mixture were added chloroform and water, the mixture was separated, and the organic layer was washed with saturated brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by thin layer silica gel chromatography (chloroform:methanol=19:1) to give 33 mg of (3S,4S)-1-(1-acetylazetidin-3-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 26.
The corresponding starting materials were used and treated in the same manner as in Example 112, to give compounds shown in the following Table 26.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give a compound shown in the following Table 26.
The corresponding starting materials were used and treated in the same manner as in Example 112, to give compounds shown in the following Table 27.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give a compound shown in the following Table 27.
To 1 ml of a dichloromethane solution containing 40 mg of the compound obtained in Example 91 cooled to 0° C. was added 23 mg of meta-chloroperbenzoic acid, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture was added an aqueous sodium hydrogen sulfite solution, and the resulting mixture was stirred at room temperature for 30 minutes, chloroform and water were added to the mixture, and the mixture was separated. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by thin layer silica gel chromatography (chloroform:methanol=19:1) to give 24 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-1-(tetrahydrothiopyran-1-oxid-4-yl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 28.
To 1.5 ml of a dichloromethane solution containing 24 mg of the compound obtained in Example 91 was added 18 mg of methanesulfonic acid, and the mixture was stirred at room temperature for 10 minutes, and then, cooled to 0° C. To the mixture was added 14 mg of meta-chloroperbenzoic acid, and the mixture was stirred at room temperature for 3 hours. To the reaction mixture were added an aqueous sodium hydrogen sulfite solution and 1M aqueous sodium hydroxide solution, the resulting mixture was stirred at room temperature for 30 minutes, chloroform and water were added to the mixture, and the mixture was separated. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by thin layer silica gel chromatography (hexane:ethyl acetate=1:1) to give 20 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-1-(tetrahydrothiopyran-1,1-dioxid-4-yl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 28.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give a compound shown in the following Table 28.
The corresponding starting materials were used and treated in the same manner as in Example 126, to give a compound shown in the following Table 29.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compounds shown in the following Table 29.
To 1 ml of a dichloromethane solution containing 127 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine cooled to 0° C. were added 11 mg of 4-morpholinecarbonyl chloride and 7.4 mg of triethylamine, and the mixture was stirred at 0° C. for 2 hours. To the reaction mixture were added dichloromethane and water, and the mixture was separated. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by basic thin-layer silica gel column chromatography (chloroform:ethyl acetate=20:1) to give 39 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}-1-(4-morpholinecarbonyl)piperidine shown in the following Table 30.
The corresponding starting materials were used and treated in the same manner as in Example 132, to give a compound shown in the following Table 30.
1.5 ml of a tetrahydrofuran solution containing 50 mg of (3S,4S)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine and 16 mg of 1,1′-carbonyldiimidazole was stirred at 50° C. for 1 hour. To the reaction mixture were added ethyl acetate and water, the mixture was separated, and the organic layer was washed with water. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. To the obtained residue were added 2 ml of acetonitrile and 0.85 g of methyl iodide, the mixture was stirred at 70° C. for 1 hour, and concentrated under reduced pressure. To the obtained residue were added 1.5 ml of tetrahydrofuran, 14 mg of 1-acetylpiperazine and 0.61 g of triethylamine, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture were added ethyl acetate and water, and the mixture was separated. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by basic thin-layer silica gel column chromatography (hexane:ethyl acetate=2:1) to give 39 mg of (3S,4S)-1-(1-acetylpiperazinecarbonyl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 30.
The corresponding starting materials were used and treated in the same manner as in Example 134, to give compounds shown in the following Table 30 and Table 31.
The corresponding starting materials were used and treated in the same manner as in Example 126, to give a compound shown in the following Table 31.
The corresponding starting materials were used and treated in the same manner as in Example 134, to give compounds shown in the following Table 31 and Table 32.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 33.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 33.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 34.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 34.
The corresponding starting materials were used and treated in the same manner as in Example 1, to give compounds shown in the following Table 35 to 39.
The corresponding starting materials were used and treated in the same manner as in Example 9, to give compounds shown in the following Table 40 to 44.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compound shown in the following Table 45.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 45.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compound shown in the following Table 45.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compound shown in the following Table 46.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 46.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compound shown in the following Table 46.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 47.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 47 and 48.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compounds shown in the following Table 48.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 49.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 49 and 50.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compounds shown in the following Table 50.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 51.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 51.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compounds shown in the following Table 51.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 52.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 52.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compounds shown in the following Table 52.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compound shown in the following Table 53.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 53.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compound shown in the following Table 53.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Tables 54 and 55.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Tables 55 to 58.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compounds shown in the following Tables 58 and 59.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compound shown in the following Table 60.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compounds shown in the following Table 60.
The corresponding starting materials were used and treated in the same manner as in Example 127, to give compound shown in the following Table 60.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compound shown in the following Table 61.
The corresponding starting materials were used and treated in the same manner as in Example 87, to give compound shown in the following Table 61.
The corresponding starting materials were used and treated in the same manner as in Example 19 to give compound shown in the following Tables 62 and 63.
The corresponding starting materials were used and treated in the same manner as in Example 75 to give compound shown in the following Table 64.
The corresponding starting materials were used and treated in the same manner as in Example 19 to give compound shown in the following Table 64.
To 2 ml of a dichloromethane solution containing 78 mg of (3S,4S)-1-(azetidin-3-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutylamino}piperidine was added 21 mg of triethylamine and 29 mg of ethyloxalyl chloride, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture were added chloroform and water, the mixture was separated, and the organic layer was washed with brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. To the obtained residue was added 1 ml of ethanol and 1 ml of 28% aqueous ammonium solution, and the mixture was stirred at 100° C. for 4.5 hours. To the reaction mixture were added ethyl acetate and water, and the mixture was separated, and the organic layer was washed with brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=19:1) to give 50 mg of (3S,4S)-1-(1-aminooxalylazetidin-3-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 64.
The corresponding starting materials were used and treated in the same manner as in Example 19, to give compounds shown in the following Table 65.
To 1 ml of a dichloromethane solution containing 45 mg of (3S,4S)-1-(azetidin-3-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutylamino}piperidine was added 0.041 ml of triethylamine and the mixture was cooling down 0° C. The mixture was added 9.5 mg of triphosgene and stirred at room temperature for 2 hours. To the reaction mixture were added ethyl acetate and semi-saturated brine, and the mixture was separated, and the organic layer was washed with brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. To the obtained residue was added 0.5 mg of dimethylaminopyridine, 1 ml of tetrahydrofran, 0.15 ml of ethylene glycol and 0.11 ml of triethylamine, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture were added ethyl acetate and water, and the mixture was separated, and the organic layer was washed with brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=9:1) to give 38 mg of (3S,4S)-1-{1-(2-hydroxyethylaminocarbonyl)azetidin-3-yl}-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 65.
To 2 ml of a dichloromethane solution containing 45 mg of (3S,4S)-1-(azetidin-3-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutylamino}piperidine was added 41 mg of trimethylsilylisocianate, and the mixture was stirred at room temperature for 16 hours. To the reaction mixture were added chloroform and a saturated aqueous sodium carbonate solution. The mixture was separated, and the organic layer was washed with brine. The organic layer was dried by using CHEM ELUT (trade name, available from VARIAN INC.), and concentrated under reduced pressure. The obtained residue was purified by thin-layer silica gel column chromatography (chloroform:methanol=9:1) to give 40 mg of (3S,4S)-1-(1-aminocarbonylazetidin-3-yl)-3-(4-fluoro-2-methylphenyl)-4-{N-methyl-2-(3,5-bistrifluoromethylphenyl)isobutyrylamino}piperidine shown in the following Table 65.
The corresponding starting materials were used and treated in the same manner as in Example 134, to give compounds shown in the following Table 65.
The corresponding starting materials were used and treated in the same manner as in Example 106, to give compounds shown in the following Table 65.
By using 3.5 g of trans-4-benzyloxycarbonylamino-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)piperidine, the same treatment as in Reference example 3(8) was carried out to give 2.4 g of trans-4-amino-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)piperidine shown in the following Table 71.
The corresponding starting materials were used and treated in the same manner as in Reference Example 1, to give compounds shown in the following Table 72.
The corresponding starting materials were used and treated in the same manner as in Reference Example 2, to give compounds shown in the following Table 72.
The corresponding starting materials were used and treated in the same manner as in Reference Example 15(1), and Example 3(4), (6) to (8) to give compound shown in the following Table 74.
The corresponding starting materials were used and treated in the same manner as in Reference Example 3(7) and (8) to give compounds shown in the following Tables 74 and 75.
To 12 ml of a methanol solution containing 1.15 g of the compound obtained in Reference Example 3(6) was added 115 mg of 10% palladium carbon, and the mixture was stirred under hydrogen atmosphere at room temperature for 2 hours. The reaction mixture was filtered through membrane filter, and the filtrate was concentrated under reduced pressure. To 13 ml of dichloromethane solution containing the obtained residue was added 31 mg of acetic acid, and the mixture was stirred at room temperature for 16 hours, and then, 658 mg of sodium triacetoxyborohydride was added and stirred at room temperature for 5 hours. To the reaction mixture were added chloroform and a saturated aqueous sodium hydrogen-carbonate solution, the mixture was separated, and the organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=95:5→4:1) to give 0.56 g of (3S,4S)-1-tert-butoxycarbonyl-3-(4-fluoro-2-methylphenyl)-4-(N-isopropylamino)piperidine shown in the following Table 75.
The corresponding starting materials were used and treated in the same manner as in Reference Example 20 to give compound shown in the following Table 75.
and
and
and
and
and
and
and
and
and
and
The “Boc” represents tert-butoxycarbonyl moiety.
The “Boc” represents tert-butoxycarbonyl moiety, and the “Bu” represents butyl moiety.
The “Bu” represents butyl moiety.
The “Boc” represents tert-butoxycarbonyl moiety.
The “Boc” represents tert-butoxycarbonyl moiety.
and
and
and
and
and
and
and
and
and
and
and
and
and
and
and
and
The “Boc” represents tert-butoxycabonyl moiety.
and
and
The compound of the present invention or a salt thereof has an excellent tachykinin receptor antagonistic action. Further, the compound of the present invention or a salt thereof is excellent in terms of safety, absorption, penetration to the brain, metabolic stability, concentration in blood and sustainability, so that it has excellent pharmaceutical effects.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2004-271221 | Sep 2004 | JP | national |
| 2005-157422 | May 2005 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP05/17555 | 9/16/2005 | WO | 2/12/2007 |
